BERLIN/LONDON April 29, 2021 - Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, announces that, due to delays in the audit of Aladdin Healthcare Technologies SE and additional time being required by the Company to finalise the 2020 annual results, the Company is not in a position to meet the deadline for the publication of its audited annual financial statements for the financial year ended 31 December 2020.
The deadline falls due Friday, 30 April 2021. The entire process of the preparation of the financial statements for the financial year 2020 has also been impacted and delayed by the work restrictions enforced by the COVID-19 pandemic.
The Company will be using its best endeavours to ensure that the audit of the annual financial statements for the financial year ended 31 December 2020 will be completed as soon as possible. The Company will publish an update regarding the time of publication as soon as it is foreseeable when the work on the financial statements can be completed.
About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.
Website Link: www.aladdinid.com
TICKER SYMBOL: NMI
For further information
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
CROSS ALLIANCE communication GmbH
Phone +49 89 1250 90330